Polymorphism in Cytochrome P4501A1 is Significantly Associated with Head and Neck Cancer Risk

Singh, Arvind Pratap; Shah, Parag P.; Ruwali, Munindra; Mathur, Neeraj; Pant, M. C.; Parmar, Devendra

doi:10.1080/07357900902849657

Cited by 32 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genetic component of AML etiology is likely to be polygenic, and the identification of further candidate genes is essential for future studies and assessment of AML risk-related genes [10][11][12]. From previous studies, the results obtained are controversial and require further investigation to confirm or clarify the data obtained.…”

Section: Introductionmentioning

confidence: 57%

“…Interestingly, in other medical settings such as solid tumors there is an increased risk for solid tumors in patients with CYP1A1 * 2A and CYP1A1 * 2C genotypes. Such evidence was reported in non-small cell lung cancer and head and neck cancer in Australian and Indian patients, respectively [10][11][12]. Experimental data from in vitro studies show that enzyme activity of CYP1A1 * 2C, is normal, but no further data support if this polymorphism in vivo can harbor a protective role to prevent DNA injury.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Increased Risk of Acute Myeloid Leukemia in Patients with CYP1A1 Polymorphisms

Pelloso¹,

Silva²,

Nogueira-de-Souza³

et al. 2013

JCT

View full text Add to dashboard Cite

Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell progenitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may account for an increased risk of AML due to partial metabolism of or biocativation of carcinogens. Chemical compounds are metabolized by a two-tiered phase detoxifying system. Polymorphisms in these pathways may lead to DNA damage and development of AML. We determined the frequencies of carcinogen metabolism gene polymorphisms (CYP1A1, del{GSTM1} and del{GSTT1}) in a case control-study based on polymorphism analysis. Fifty-eight consecutively AML patients (median age 62 years) and 174 sex and age-matched control group were assessed by a PCR-RFLP assay. There were 51 de novo and 7 secondary AML. CYP1A1 * 2A and CYP1A1 * 2C polymorphisms were more frequent in CG than AML p < 0.001 and in contrast, CYP1A1 * 3 and CYP1A1 * 4 were more frequent in AML than CG p < 0.001. There were no differences in del{GSTM1} neither del{GSTT1} between AML and CG (p = 0.999 and p = 0.539). Odds ratio for AML in patients harboring CYP1A1 * 3 was 2.36 (95% CI 1.2 -4.5), 2.38 for CYP1A1 * 4 (95% CI 0.8 -6.8). Adjusted OR was 2.63 for CYP1A1 * 3 (95% CI 1.4 -5.1) and 2.66 for CYP1A1 * 4 (95% CI 0.9 -7.8). In the multivariate analysis CYP1A1 * 3 polymorphism was a risk factor for AML with an OR for 3.99 (95%CI 1.9 -8.6). To the best of our knowledge this is the first study to show that CYP1A1 * 3 heterozygous genotypes increase the risk of AML. Our data support that inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.

show abstract

Section: Introductionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 85%

Increased Risk of Acute Myeloid Leukemia in Patients with CYP1A1 Polymorphisms

Pelloso¹,

Silva²,

Nogueira-de-Souza³

et al. 2013

JCT

View full text Add to dashboard Cite

show abstract

“…When the genotypes were included in analyses, we initially found similar frequencies of the CYP1A1 A4889G and T6235C and GSTM1 and GSTT1 genotypes in patients and controls, suggesting that the polymorphisms did not alter the risk for HNSCC, according to previous evaluations [8,9,[18][19][20][21][22][23]. In contrast, increased risks for disease in carriers of the variant alleles of the CYP1A1 A4889G [22,24] and T6235CC [22,[25][26][27][28] and the GSTM1 [8,23,25,26,[28][29][30][31][32] and GSTT1 null [26,33] genotypes were also previously reported.…”

Section: Discussionmentioning

confidence: 94%

CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma

et al. 2011

View full text Add to dashboard Cite

We examined the influence of the CYP1A1 A4889G and T6235C, GSTM1 and GSTT1 polymorphisms, involved in carcinogen metabolism, on the head and neck (HN) squamous cell carcinoma (SCC) risk. DNA from 142 HNSCC patients and 142 controls was analysed by polymerase chain reaction (PCR)-restriction fragment length polymorphism or multiplex-PCR for the polymorphisms analyses. Excesses of the CYP1A1 4889AG+GG and 4889AG+GG plus GSTT1 null genotype were seen in patients with heavy tobacco habit compared with controls (41.9% versus 26.8%, P = 0.03; 26.2% versus 10.3%, P = 0.04, respectively). Carriers of the referred genotypes and heavy tobacco consumption were under a 2.0-fold and 2.8-fold increased risks for HNSCC than others, respectively. The CYP1A1 6235TC+CC plus GSTM1 and GSTT1 null genotypes were more common in pharyngeal SCC patients than in controls (5.3% versus 0.7%, P = 0.04). Carriers of the combined genotype had 16.0-fold increased risk for the disease than others. The frequency of one null genotype of the GSTM1 or GSTT1 gene was higher in patients with pharyngeal SCC and heavy smoking status than in controls (76.3% versus 57.7%, P = 0.04). Carriers of the referred genotype and heavy tobacco status had a 2.4-fold increased risk for pharyngeal SCC than others. In contrast, the CYP1A1 6235TC+CC genotype was more common in controls than in laryngeal SCC patients (35.9% versus 21.6%, P = 0.01). Carriers of the genotype had a 0.2-fold decreased risk for the disease than others. Our data present preliminary evidence that inherited combined CYP1A1 A4889G and T6235C abnormalities and GSTM1 and GSTT1 pathways are important determinants of HNSCC, particularly pharyngeal SCC in heavy smoking individuals from south-eastern Brazil.

show abstract

“…The characteristics of the selected studies are listed in table 1. Among these studies [22,23,24,25,26,27,28,29,30,31,32,33], the distribution of genotypes in the controls of 6 studies was in agreement with the HWE. For CYP2D6*4 polymorphism, our meta-analysis contained 5 comparisons with 991 cases and 1,010 controls [16,30,34,35,36].…”

Section: Resultsmentioning

confidence: 67%

“…In total, 12 studies [22,23,24,25,26,27,28,29,30,31,32,33] examined the association between CYP1A1 polymorphism and the risk of HNSCC. The results are listed in supplemental table 1 (www.karger.com/?DOI=000363428) .…”

Section: Resultsmentioning

confidence: 99%

Meta-Analyses of the Effect of CYP1A1 and CYP2D6 Polymorphisms on the Risk of Head and Neck Squamous Cell Carcinoma

Han¹,

Wang

Yang

et al. 2014

Oncol Res Treat

View full text Add to dashboard Cite

Background: CYP1A1 and CYP2D6 are important genes encoding enzymes involved in the metabolism of toxic chemicals and carcinogens. However, inconclusive results for the association between CYP1A1 and CYP2D6 polymorphisms and the risk of head and neck squamous cell carcinoma (HNSCC) have been reported. We conducted a meta-analysis to evaluate the association of CYP1A1 and CYP2D6 polymorphisms with the risk of HNSCC. Methods: A database search yielded 19 relevant studies. 3 polymorphisms were included in the meta-analysis: CYP1A1, CYP2D6*4 and CYP2D6*10. Random or fixed effect models were used in the analysis. Results: The CYP1A1 polymorphism was associated with HNSCC (for m1m1 vs. m1m2: odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.030-1.542, p_{heterogeneity} = 0.025; for the recessive model: OR = 1.316, 95% CI = 1.065-1.625, p_{heterogeneity} = 0.001). The analysis showed evidence for association between the CYP2D6*4 polymorphism and HNSCC in Asian populations; however, negative results were also observed in other models. A significant association was also observed between CYP2D6*10 polymorphism and HNSCC risk. Conclusions: The current study demonstrates that the CYP1A1 and CYP2D6 polymorphisms are associated with susceptibility to both development and progression of HNSCC.

show abstract

Polymorphism in Cytochrome P4501A1 is Significantly Associated with Head and Neck Cancer Risk

Cited by 32 publications

References 36 publications

Increased Risk of Acute Myeloid Leukemia in Patients with <i>CYP</i>1<i>A</i>1 Polymorphisms

Increased Risk of Acute Myeloid Leukemia in Patients with <i>CYP</i>1<i>A</i>1 Polymorphisms

CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma

Meta-Analyses of the Effect of <b><i>CYP1A1</i></b> and <b><i>CYP2D6</i></b> Polymorphisms on the Risk of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About

Polymorphism in Cytochrome P4501A1 is Significantly Associated with Head and Neck Cancer Risk

Cited by 32 publications

References 36 publications

Increased Risk of Acute Myeloid Leukemia in Patients with &lt;i&gt;CYP&lt;/i&gt;1&lt;i&gt;A&lt;/i&gt;1 Polymorphisms

Increased Risk of Acute Myeloid Leukemia in Patients with &lt;i&gt;CYP&lt;/i&gt;1&lt;i&gt;A&lt;/i&gt;1 Polymorphisms

CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma

Meta-Analyses of the Effect of <b><i>CYP1A1</i></b> and <b><i>CYP2D6</i></b> Polymorphisms on the Risk of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About

Increased Risk of Acute Myeloid Leukemia in Patients with <i>CYP</i>1<i>A</i>1 Polymorphisms

Increased Risk of Acute Myeloid Leukemia in Patients with <i>CYP</i>1<i>A</i>1 Polymorphisms